Clinical studies participated by three investigators to be presented at ASH Annual Meeting and Exposition

November 25, 2015

Five other investigators affiliated with US Oncology Research were involved in a poster abstract that will be displayed at the conference on the evening of Saturday, Dec. 4.

"This is a poster describing an exciting study which is underway in US Oncology Research," said Nicholas Di Bella, M.D., oncologist for Rocky Mountain Cancer Centers ?? Aurora. "Using special gene expression technology, we can identify patients with lymphoma who are relatively resistant to standard therapy with R-CHOP. Patients with lymphoma with the non-germinal center B cell profiles may not respond to this combination, so these patients are being treated with standard R-CHOP or R-CHOP plus the new agent Bortezomib, which may overcome the natural resistance of lymphoma cells to R-CHOP."

Many clinical studies led by US Oncology Research Network physicians were also predominantly featured at numerous conferences held around the world, including the annual congress for the European Society for Medical Oncology (ESMO), the annual meeting for the American Society for Clinical Oncology (ASCO) and the upcoming San Antonio Breast Cancer Symposium (SABCS). Those studies, along with more than 30 published manuscripts, featured forward looking clinical research topics that are helping advance cancer care today and discover improved therapies for the cancer care of tomorrow.

SOURCE US Oncology, Inc.